MGC Pharmaceuticals continues to put the building blocks in place for its seed-to-pharmacy medicinal cannabis business. It has received its first formal purchase orders for CannEpil in the UK, and has already received repeat orders from new distributors in Australia. It recently appointed distributors for Brazil, Germany, Austria and Switzerland. Its Phase II study of CogniCann in dementia is recruiting faster than expected. Preliminary approvals are in place for its Malta production hub, but it will need to raise funds for construction. We adjust our valuation to A$157m (vs A$135m).Den vollständigen Artikel lesen ...
10.07.2019 | 14:58
(42 Leser)
(42 Leser)
(0 Bewertungen)
Edison Investment Research · Mehr Nachrichten von Edison Investment Research
© 2019 Edison Investment Research
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | MGC PHARMACEUTICALS LTD: Annual Report 2019 | ||
| Fr | MGC PHARMACEUTICALS LTD: Appendix 4G and Corporate Governance Statement | ||
| Mi | 600 prescriptions have now been written for MGC Pharma medicinal cannabis products | ||
| Mi | MGC PHARMACEUTICALS LTD: 600 Prescription Milestone Passed for MGC Pharma Products | ||
| 03.10. | MGC Pharma growth accelerates as prescription sales double in two weeks |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
